Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Recifercept in Healthy Participants
NCT04543344Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised trial of recifercept in achondroplasia (ACH) (3 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time, Area Under the Curve From Time Zero to End of Dosing Interval and 4 more. Started Sep 2020; status: completed.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT04543344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543344.